Close Menu
June 16, 2021
Sponsored by
Biognosys

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

GenomeWebinar

Director of the Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics,
National Tumor Institute “Fondazione G. Pascale” 

Clinical Services Manager,
Biognosys 

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Immune checkpoint inhibitors have proven to be an effective weapon against many solid tumors, but a large proportion of patients do not show a clinical benefit upon treatment. While studies have identified genomic or transcriptomic features responsible to some extent for the lack of response, major advancements in mass spectrometry-based proteomics have only recently enabled comprehensive functional analysis of the final gene products on an unprecedented scale, enabling quantitative and clinically relevant analysis of response mechanisms.

In this webinar, Paolo A. Ascierto, MD of Italy’s National Tumor Institute and Kamil Sklodowski of Biognosys will elaborate on the promise of proteomics for addressing the unmet medical needs of melanoma patients undergoing immunotherapy. 

They will discuss data from a joint project in which cancer tissue samples from late-stage melanoma patients prior to treatment with immune checkpoint inhibitors were analyzed using the Biognosys HRM discovery platform. 

They will share the clinical outcomes as well as the associated proteomic profiles of more than 8,500 identified and quantified proteins, providing a full picture of the capabilities of next-generation proteomics.

About The Series: Next-Generation Proteomics for Precision Oncology

This webinar series will highlight recent advancements in the proteomics field and the impact of proteomics on clinical research in oncology.

Sponsored by

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

Apr
20
Sponsored by
Olink

This webinar will discuss a study that sought to identify early biomarkers for cancer by analyzing pre-diagnosis samples from seemingly healthy individuals who were later diagnosed with cancer.

Apr
22
Sponsored by
10x Genomics

The human immune system is extremely complex, comprised of multiple cell types and states interacting in myriad ways to produce diverse cellular ecosystems.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Apr
28
Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development.